Jean-Marie Lambert

Jean-Marie Lambert

Auto-generated profile, based on publicly available information

Jean-Marie Lambert

UMR CNRS 7276, Inserm 1262, Université de Limoges - CRIBL (Control of the B-cell Immune Response and Lymphoproliferations), Team3 BioPIC (Biology of Plasma Cells, Immunopathology and Cancer), Limoges, France; Present address: Université Côte d'Azur, CNRS, Molecular and Cellular Pharmacology Institute, Valbonne, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025
Verified
Book Chapter
Closed access
PDF file
APAntoine Praité
Antoine Praité
JLJean-Marie Lambert
Jean-Marie Lambert
LDLaurent Delpy
Laurent Delpy
SHSandy Al Hayek
Sandy Al Hayek

24 July 2025
Verified
Book Chapter
Closed access
SHSandy Al Hayek
Sandy Al Hayek
APAntoine Praité
Antoine Praité
JLJean-Marie Lambert
Jean-Marie Lambert
SBSébastien Bender
Sébastien Bender
LDLaurent Delpy
Laurent Delpy

29 June 2026 in Journal of Molecular Biology
Verified
Journal Article
Open access
APAntoine Praité
Antoine Praité
JLJean-Marie Lambert
Jean-Marie Lambert
MAMohamad Omar Ashi
Mohamad Omar Ashi
ETEstelle Troadec
Estelle Troadec
COChristelle Oblet
Christelle Oblet
LDLaurent Delpy
Laurent Delpy
Plasma cells are terminally differentiated B lymphocytes specialized in the high‑level production and secretion of antibodies. To accommodate the persistent load imposed on the endoplasmic reticulum (ER), plasma cell differentiation engages a sustained unfolded protein response (UPR). Although the UPR is known to attenuate nonsense‑mediated mRNA decay (NMD) in many cell types, the interplay between these pathways during plasma cell differentiation remains poorly defined. We show that NMD is rapidly enhanced during B cell activation and remains high in antibody‑secreting cells (ASCs), even as these cells activate the UPR. Using mouse models enabling in vivo monitoring of NMD under enforced ER stress, we identify limited activation of the PERK-eIF2α axis as a key determinant preserving NMD activity while supporting robust immunoglobulin synthesis. Supporting a key role for NMD in B cell activation and ASC differentiation, antisense oligonucleotide‑mediated knockdown of Upf1 severely compromised cell viability. Moreover, we provide evidence for efficient degradation of endogenous NMD substrates in myeloma cells, suggesting a functional role for NMD in multiple myeloma. Taken together, these findings reveal an integrated protein quality‑control network in ASCs that relies on the coordinated action of NMD and non‑canonical UPR signaling to maintain proteostasis and support massive immunoglobulin synthesis.

2 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JLJean-Marie Lambert
Jean-Marie Lambert
APAntoine Praité
Antoine Praité
MCMarion Contini
Marion Contini
MAMohamad Omar Ashi
Mohamad Omar Ashi
AMAnne Marchalot
Anne Marchalot
LDLaurent Delpy
Laurent Delpy
Deregulated proliferation of a plasma cell (PC) clone is accompanied by an excess production of a monoclonal immunoglobulin (mo-Ig) component with unique V(D)J rearrangement features. In systemic Ig light chain (AL) amyloidosis, organ dysfunction is due to the deposition of amyloid fibrils composed of mo-Ig light chains in target tissues. Recent advances in exon skipping therapy using splice-switching antisense oligonucleotides (ASO) prompted us to examine a new antisense strategy targeting the variable (V) exon in myeloma cells. Indeed, we previously observed that the production of truncated Ig light chains, encoded by alternatively spliced mRNAs lacking V exon, heightened endoplasmic reticulum (ER) stress and triggered apoptosis of antibody-secreting plasma cells. We designed ASO hybridizing donor or acceptor V exon splice sites on mo-Ig pre-mRNAs. These compounds were very potent alternative splicing inducers and increased the production of V-domain-less truncated Ig chains. Remarkably, in vitro experiments and tumor xenograft models revealed that myeloma cells were highly sensitive to specific ASO treatment, compared to an irrelevant control-ASO. RNA-seq experiments further confirmed that the production of truncated Ig induced upon ASO treatment provoked a massive myeloma cell death through ER stress-associated apoptosis. In addition, high throughput sequencing of Ig repertoire demonstrated that ASO targeting JH2 or Jκ1 donor splice site induced massive elimination of VDJH2- or VJκ1-rearranged clones respectively, while sparing the others. Collectively, these data provide evidence that ASO targeting V exon on mo-Ig pre-mRNAs can emerge as new weapons to induce selective killing of plasma cell clones.

4 April 2026
Verified
Thesis
Closed access
JLJean-Marie Lambert
Jean-Marie Lambert
Les projets développés au cours de cette thèse ont pour objectif d’explorer l’intérêt thérapeutique d’approches antisens ciblant les transcrits d’immunoglobulines (Ig) dans le traitement du myélome multiple (MM) et d’autres gammapathies monoclonales. Cette stratégie consiste à provoquer un saut d’exon à l’aide d’oligonucléotides antisens (ASO) pour induire la synthèse d’Ig tronquées et l’apoptose des plasmocytes tumoraux (Brevet WO 2017/089359). L’effet toxique des Ig sans domaine V résulte d’une amplification incontrôlée du stress du RE et de la réponse UPR (« Unfolded Protein Response »). Nous avons montré que des traitements à l’aide d’ASO dirigés contre les ARN pré-messagers de l’Ig monoclonale induisaient une forte toxicité dans des lignées de myélome et une régression tumorale dans un modèle de xénogreffe avec des injections intratumorales d’ASO. Bien que des améliorations en terme de biodistribution in vivo de ces ASO soient nécessaires, cette approche capable de cibler spécifiquement le clone tumoral en épargnant les plasmocytes sains pourrait permettre un traitement personnalisé des patients atteints de MM. De surcroît, nous avons également observé une diminution drastique de la production d’Ig à la suite d’un traitement par un ASO générique ciblant l’exon CH1γ, aussi bien dans les LB humains stimulés ou dans des lignées de myélome; cet ASO pouvant être utilisé chez tous les patients exprimant une IgG. En parallèle, nous avons exploré les liens entre stress protéique et surveillance des ARN dans les plasmocytes. Contrairement aux données de la littérature concernant des cellules non-lymphoïdes, nous avons mis en évidence une coopération entre le mécanisme de NMD (« Nonsense-Mediated mRNA Decay ») et l’UPR (« Unfolded Protein Response ») dans les plasmocytes, qui est rendue possible grâce par une faible activation de la voie PERK de l’UPR. Cette thèse a pour but de mieux comprendre l’impact des Ig tronquées dans les cellules sécrétrices d’anticorps et le lien étroit entre survie des plasmocytes et stress protéique associé à la synthèse massive d’Ig.